Experienced Product Lead with a strong background in oncology, specializing in Tivdak (tisotumab vedotin-tftv), the first antibody-drug conjugate (ADC) for adults with previously treated recurrent or metastatic cervical cancer, and the pipeline product disitamab vedotin (HER2-directed ADC).Key Responsibilities:-Develop and maintain diverse scientific resources (letters, slides, posters, abstracts, dossiers, FAQs).-Review and approve medical accuracy in promotional, educational, and training materials.-Collaborate on proposal letters to NCCN and compendia groups.-Lead company-wide alerts on NCCN guideline changes.-Conduct QA/QC Call-Center reviews and address escalations.-Lead MedInfo contractor and Fellow training.-Address ad-hoc inquiries from MSL and sales reps.-Disseminate monthly inquiry reports.-Support deliverables and global inquiries related to other commercial products.Notable Achievements:-Contributed to the NCCN submission letter focused on overall survival outcomes, leading to ADCETRIS becoming a preferred treatment option for patients with untreated stage III/IV cHL and no known neuropathy.-Created deliverables to support what was the new indication of ADCETRIS and its use in pediatric patients with untreated high-risk cHL.-Established Seagen's first-ever MedInfo Style Guide.-Collaborated on the creation of the inaugural Call-Center Handling Guide.-Developed and maintained the pioneering Dossier Repository SharePoint site.

Product lead of legacy product ADCETRIS (CD30-directed ADC) covering North America, and the pipeline product disitamab vedotin (HER2-directed ADC).

Developed and updated Xofigo and darolutmide medical information letters and Q&As as part of Bayer's global medical affairs oncology division. Content addresses questions on product efficacy, safety, administration, and use from healthcare providers.

Managed and analyzed technical data of clinical study samples performed by Advanced Diagnostics Laboratory at National Jewish Health. Primary point of contact specific to the phase II study by Cytosorbents, Refresh II. Utilizing Smartsheet, Tableau, and Salesforce, produced accurate data management for all clients.

Contributed to the creation and release of content during the development of the migraine drug Aimovig (erenumab-aooe). Trained external contractors to curate medical literature related to migraine and erenumab. Created and provided content in response to erenumab-related inquiries from healthcare providers. Additional responsibilities included:• Creation, collaboration, and updates of erenumab medical information letters (intended for healthcare providers).• Organization and storage of clinical literature for use by regional medical liaisons.• Support of separate therapeutic areas by searching for content and responding to requests related to other pipeline drugs.Maximized contract from a six month trial period to a term-limit three year commitment.

Employer contracted with Amgen to provide customers with medical information related to Amgen legend drugs. Responsibilities include, but not limited to, responding to medication inquiries, reporting of adverse events and product complaints, training of new staff, and medical writing. Additional experiences include:• Training of new staff with Neulasta and Neupogen information, and related phone skills.• Implementation of monthly clinical education presentations for the staff.• Created workflow templates, maximizing intake information and minimizing phone time.• Created end-user checklist to maximize required intake information.• Speaker at student APhA representing Rocky Mountain Poison and Drug Center.• Direct customer-focused service and care.

Responsible for pharmacy P&L, staffing, inventory.• More than doubled prescription volume during tenure.• Developed prescription delivery program.• Integration of new business from pharmacy acquisition.• Prepared, verified and dispensed prescriptions.• Patient-centered care.